Gilead’s Dual-Action HIV Breakthrough: Single-Tablet Bictegravir-Lenacapavir Regimen Shows Promise in Phase 3 Trial

Gilead Sciences announced positive topline results from the Phase 3 ARTISTRY-2 trial on December 15, 2025 and reported by Drugs.com, marking a significant advancement in HIV treatment options. The trial…

Continue Reading Gilead’s Dual-Action HIV Breakthrough: Single-Tablet Bictegravir-Lenacapavir Regimen Shows Promise in Phase 3 Trial

CDC Endorses Twice-Yearly HIV Prevention Drug Yeztugo, But Access Barriers Remain

In a significant advancement for HIV prevention, the Centers for Disease Control and Prevention (CDC) has issued a strong recommendation for Yeztugo (lenacapavir), Gilead Sciences’ long-acting, twice-yearly pre-exposure prophylaxis (PrEP)…

Continue Reading CDC Endorses Twice-Yearly HIV Prevention Drug Yeztugo, But Access Barriers Remain
Rare Community Profiles: How Patient Advocate Kecia J. Survived and Thrived Through Her Rare Colorectal Cancer Battle
source: pixabay.com

Rare Community Profiles: How Patient Advocate Kecia J. Survived and Thrived Through Her Rare Colorectal Cancer Battle

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: How Patient Advocate Kecia J. Survived and Thrived Through Her Rare Colorectal Cancer Battle